E

Exscientia

AI-Driven Drug Discovery

Oxford, UK (US: Miami, Boston)
500+

About Exscientia

Industry: TechBio
Founded: 2012
Founders: Andrew Hopkins
Status: Public (NASDAQ: EXAI)

Funding & Growth

Total Raised: $600M+
Valuation: $2B+ market cap
Stage: Public
Key Investors:
SoftBank Bristol Myers Squibb Evotec

✓ Pros

  • • AI-first drug discovery pioneer
  • • Multiple pharma partnerships
  • • Growing US presence
  • • First AI-designed drug in trials
  • • Strong scientific publications

✗ Cons

  • • UK headquarters
  • • Smaller US team
  • • Stock volatility
  • • Clinical-stage risk

Get weekly job alerts